ArticleBMC pediatrics2026
KCNJ11 (p.Arg192Cys)-associated MODY13 with coexisting autoimmunity in a child, a case report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaturity-onset diabetes of the young type 13 (MODY13) is a rare autosomal dominant monogenic diabetes caused by mutations in the potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) gene. It can mimic both type 1 and type 2 diabetes mellitus (T1DM and T2DM), making accurate diagnosis challenging. CASE PRESENTATION: We describe the case of a five-year-old boy with overlapping features of T1DM and T2DM. He presented with hyperglycemia, obesity, and acanthosis nigricans. These symptoms improved after losing 11 kg owing to lifestyle modifications. His hemoglobin A1c (HbA1c) level decreased from 9.6% to 5.8%, and the continuous glucose monitoring system (CGMS) showed 91% time in range (TIR). Eighteen months later, he developed postprandial hyperglycemia and tested positive for T1DM antibodies, prompting the administration of insulin at 0.7 U/kg/day. His glucose levels continued to fluctuate. Whole-exome sequencing identified a likely pathogenic KCNJ11 variant (NM_000525.3, c.574 C > T, p.Arg192Cys), confirming the diagnosis of heterozygous autosomal dominant MODY13. He was then started on oral glibenclamide at 0.2 mg/kg/day, which lowered his HbA1c level to 7.5% and raised his CGMS TIR readings to 70%; however, insulin dependence persisted because of ongoing autoimmune β‑cell destruction.
conclusionsThis case demonstrates the diagnostic challenge in pediatric diabetes when the features of T1DM, T2DM, and MODY overlap. Prompt genetic testing can lead to precise therapy. The simultaneous appearance of MODY13 and autoimmunity suggests possible interactions between the gene and the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.